The 1,000km for Kom op tegen Kanker cycling event has once again captured the hearts of Belgium, raising a record-breaking amount for cancer research. This year’s four-day event saw 1,329 teams pedal with passion, generating impressive support for patient-focused cancer studies. As of 2025-06-01 21:18:00, the official figures have been confirmed, highlighting the event’s growing impact.
- Veertiende editie 1.000km bracht 7,4 miljoen euro op
- 1.329 teams namen deel aan fietsevenement
- Opbrengst gaat naar patiëntgericht kankeronderzoek
- Wegkapitein Ludo Dierckxsens overleed tijdens evenement
- Organisatie verwacht opbrengstbedrag nog te stijgen
- Vorig jaar 6,925 miljoen euro ingezameld
In a touching moment during the closing ceremony at Mechelen’s Grote Markt, participants honoured the memory of Ludo Dierckxsens, a beloved former cycling champion and road captain who tragically passed away during the event. His legacy continues to inspire the cycling community and supporters of Kom op tegen Kanker.
What makes this event so successful year after year, and how does it continue to rally such strong local support? The answers lie not only in the dedication of the cyclists but also in the shared commitment to a cause close to many Belgian hearts.
Why does the 1,000km event resonate so deeply in Belgium? It’s more than just a race; it’s a community effort that brings people together for a meaningful cause. Key factors include:
- Strong participation with a record 1,329 teams showing widespread engagement
- Significant fundraising surpassing last year’s €6.925 million total
- A heartfelt tribute to Ludo Dierckxsens, reinforcing community bonds and motivation
- Full transparency with all proceeds dedicated to patient-centred cancer research
Looking ahead, how can more Belgians get involved in this inspiring event? Whether as participants, sponsors, or supporters, everyone can contribute to this growing movement. The 1,000km for Kom op tegen Kanker proves that collective action can drive hope and progress in the fight against cancer.
